Overview
- The U.S. Food and Drug Administration approved the weekly subcutaneous starter dose for Leqembi, a change reported Monday that allows some patients or caregivers to begin treatment at home with an autoinjector.
- Regulators relied on pharmacokinetic bioequivalence and exposure‑response modeling showing weekly 500 mg subcutaneous dosing produces drug exposure similar to the biweekly 10 mg/kg intravenous regimen rather than on new large outcome trials.
- Data presented at the Alzheimer’s Association International Conference and Clarity AD substudies reported comparable amyloid plaque reduction and short‑term clinical markers between subcutaneous and intravenous routes.
- Available safety findings showed generally similar tolerability with fewer systemic infusion reactions for subcutaneous use but limited follow‑up and small cohorts leave questions about long‑term ARIA risk, diverse‑population effects, and real‑world adherence.
- Advocates say at‑home dosing could boost access and make long‑term or combination Alzheimer’s regimens more feasible, while clinicians, payers, and researchers will monitor uptake, safety signals, and clinical outcomes over time.